What Can CIDP Treatment Realistically Improve? Setting Expectations With Your Neurologist

The stairs were the first thing he mentioned. Not the numb feet, not the tingling fingers, but the fact that he had started counting the steps to his front door and pausing halfway up. By the time the diagnosis of chronic inflammatory demyelinating polyneuropathy landed, he had one question for the neurologist that had nothing to do with acronyms: will I get the stairs back?

That is the real shape of the question behind what to expect from CIDP treatment. People do not want a lecture on immunology. They want to know which losses are recoverable, which are probably permanent, how long the waiting takes, and how they will recognize progress when it is slow enough to miss.

The honest answer has layers. Some improvements are common and arrive within weeks. Others take months and depend on how much of the nerve was damaged before treatment began. A few things treatment cannot promise at all, and knowing that up front is not pessimism. It is the difference between a plan and a hope.

What to expect from CIDP treatment: the honest headline

Start with the goal, because it is narrower and more achievable than many people assume. Treatment for CIDP aims to stop the immune system from attacking the insulating coating of peripheral nerves, and by doing so to let strength and function return as far as the underlying nerve fibers allow. It is a disease-control strategy, not a rebuild-from-scratch strategy.

CIDP is a chronic condition in which the immune system damages myelin, the fatty sheath that wraps nerve fibers and lets electrical signals travel quickly. The National Institute of Neurological Disorders and Stroke (NINDS) describes it as a disorder marked by progressive weakness and impaired sensation in the arms and legs, with symptoms that develop over two months or more. That slow, grinding timeline is part of what separates it from its acute cousin, Guillain-Barré syndrome, and it is also why recovery tends to be slow.

What treatment commonly improves, according to NINDS and MedlinePlus, is muscle strength, walking, balance and the ability to do ordinary tasks such as buttoning a shirt or climbing stairs. What it improves less predictably is sensation, particularly deep numbness in the feet, and fatigue. What it cannot do is promise a fixed endpoint: some people respond to their first therapy and stay well with maintenance, others cycle through two or three approaches before finding one that holds, and a minority have a form that responds poorly to standard options.

The most useful expectation to carry into the consulting room is this: treatment is judged by whether the decline stops and function creeps back, measured against your own baseline, not against a picture of full health. Your neurologist will set that baseline early, often with grip strength, timed walks and standardized scales, precisely so that the two of you can later tell the difference between real change and a good or bad day.

How CIDP treatment actually works in plain language

Picture an electrical cable. The copper wire in the middle is the axon, the long fiber that carries the nerve signal. The plastic insulation around it is myelin. In CIDP, immune cells and antibodies strip patches of that insulation. Signals slow down, leak, or fail to arrive, and the muscles at the far end grow weak while the skin reports numbness or pins and needles.

Every first-line treatment works on the same principle: calm the immune attack so the insulation can be repaired. The body’s own myelin-producing cells, called Schwann cells, can relay a damaged nerve segment once the assault stops, which is why strength can return relatively quickly in people whose axons are still intact. The treatments differ in how they achieve that calm.

Immune globulin therapy, usually shortened to IVIG when given into a vein, is a purified pool of antibodies from many donors. MedlinePlus lists it among the standard approaches; it appears to work by flooding the system with normal antibodies that dilute and interfere with the harmful ones, and by dampening several arms of the immune response at once. Corticosteroids are synthetic versions of the body’s stress hormone; they broadly suppress inflammation. Plasma exchange physically removes the liquid part of the blood, which carries the misdirected antibodies, and replaces it with a substitute fluid.

None of these repairs the nerve directly. They buy the nerve time and quiet. That distinction matters for expectations: if a therapy is working, the first evidence is often that things stop getting worse, and only later that they get better. NINDS notes that early treatment can help limit lasting nerve damage, and the reason is exactly this. Insulation regrows; a severed wire does not regrow so easily.

Who is usually offered treatment, and who is usually asked to wait

Treatment is typically offered when the diagnosis is reasonably secure and the disease is causing measurable disability or is clearly progressing. Both parts of that sentence carry weight.

The diagnosis part is not a formality. CIDP is confirmed by combining the story of symptoms with a nerve conduction study, a test that measures how fast and how strongly electrical signals travel along nerves, and often electromyography, which records the electrical activity of muscles. NINDS and MedlinePlus both describe these as central to diagnosis, sometimes supported by a spinal fluid sample or, less often, a nerve biopsy. Neurologists take care here because several other neuropathies, including those linked to diabetes, certain blood protein disorders and inherited conditions, can mimic CIDP, and immune therapies would not help them.

The disability part is a judgment call made with you. Someone who is tripping on curbs, dropping cups or losing the ability to work is a clear candidate. Someone with mild tingling, stable strength on repeat testing and no functional loss may be asked to wait, with a follow-up examination in a few weeks or months, so that the team can see whether the condition is truly active before committing to therapies that carry their own risks and demand a long-term schedule.

People are also sometimes asked to pause before a specific option rather than before treatment as a whole. Corticosteroids may be avoided or delayed in people with poorly controlled diabetes, fragile bones or a history of serious infection. Plasma exchange requires reliable vein access and a center equipped to perform it. Immune globulin may be approached cautiously in people with certain kidney or clotting histories. These are not refusals; they are the team steering toward the option most likely to help you specifically. If you are told to wait, ask what would change the decision and when you will be reassessed.

What "improvement" means in CIDP: strength, sensation, fatigue

Ask five people with CIDP what improvement means and you will hear five answers. Ask five neurologists and you will hear one word: function. The gap between those answers is where disappointment hides, so it is worth separating the layers.

Strength is the layer that responds best and is measured most easily. Weak muscles served by demyelinated but intact nerve fibers often regain power once conduction improves. Grip strength, the ability to rise from a chair without using hands, and walking distance are the usual yardsticks. Many clinics use standardized disability scales at each visit for this reason.

Sensation is slower and less complete. Numbness, especially in the feet, reflects damage to sensory fibers that are among the longest in the body, and NINDS describes sensory loss as a core feature that can persist. Some people notice that tingling settles before numbness lifts; others find that the numb patch shrinks but never disappears. Balance often improves as strength returns even when foot sensation stays dulled, because muscles compensate.

Fatigue and pain form a third layer. Neuropathic pain, meaning pain generated by injured nerves rather than by tissue damage, may ease as inflammation settles, but the NHS notes that nerve pain frequently needs its own management alongside treatment of the cause. Fatigue in chronic neurological conditions is common and only partly tracks nerve recovery.

A practical way to hold this together is to write down, before treatment starts, three tasks you cannot do or do badly and to revisit that list at each appointment. Stairs without a pause. Opening a jar. Standing to cook a meal. Those are the units in which CIDP treatment is realistically judged, and they are the ones your neurologist is most interested in hearing about.

How quickly does CIDP treatment work?

Slowly, then sometimes all at once, then slowly again. That is the honest rhythm, and it varies by treatment.

Plasma exchange tends to act fastest. Because it removes circulating antibodies directly, some people notice change within days of a course. The catch, as MedlinePlus and NINDS both note, is that the benefit is usually temporary. Antibodies are produced continuously, so without something to stop production the effect fades over weeks.

Immune globulin therapy commonly shows an effect within a few weeks of the first course, though neurologists generally judge response after a complete initial course and the first maintenance interval rather than after a single infusion. Corticosteroids are typically the slowest of the three to show benefit; improvement often builds over weeks to a few months, which is why they are sometimes combined with a faster-acting option at the outset or reserved for people who tolerate them well.

Underneath all of this sits a biological speed limit. Myelin can be repaired within weeks once the attack stops. Axons that have been lost regrow, if at all, at roughly an inch a month according to NINDS, and only when the supporting structure of the nerve is intact. Weakness caused by lost axons therefore recovers over many months, and sometimes not fully.

Two expectations follow. First, you should not judge a therapy as failed after a single session, and your team will usually want a defined trial period before switching. Second, a therapy that halts progression without producing visible gains in the first month has not necessarily failed either; it may be doing the essential job while slower repair catches up. Ask your neurologist at the start how long the planned trial is and what measurement will decide whether it is working.

First-line CIDP treatment options compared

Three approaches carry the strongest evidence and are named as standard options by NINDS and MedlinePlus. The table below summarizes what each does and what people commonly ask about it. Nothing in it is a recommendation; the choice depends on your health history, other conditions, veins, lifestyle and preferences, and it belongs with your treating team.

Option	How it works	Typical onset of effect	Common practical considerations
Immune globulin (IVIG, or a subcutaneous form)	Pooled donor antibodies dampen the misdirected immune response	Often within weeks of the initial course	Requires repeated infusions on a schedule set by the team; headache, fatigue and flu-like symptoms around infusions are common; rare kidney and clotting risks
Corticosteroids	Broad suppression of inflammation	Usually weeks to a few months	Taken by mouth or given by infusion; long-term use raises concerns about blood sugar, bone density, weight, mood and infection, so monitoring is built in
Plasma exchange	Removes antibody-containing plasma and replaces it	Often within days	Needs good vein access and a specialized setting; effect fades over weeks unless combined with another therapy

A few points the table cannot capture. Response to one option does not predict response to another; someone who gains little from corticosteroids may respond well to immune globulin, and vice versa. Side-effect profiles matter as much as speed for a therapy you may use for years. Ask which of the three your team is leaning toward, why that one for you, and what the fallback would be.

What the first weeks and months of CIDP treatment usually look like

The first appointment after a diagnosis often feels like a hinge: everything before it was about finding the cause, and everything after is about living with the plan. Here is the ordinary sequence, drawn from how NINDS, MedlinePlus and NHS materials describe management.

Week one to two. Baseline measurements are recorded: grip strength, a timed walk, a disability score, sometimes repeat nerve conduction studies. Blood tests check kidney and liver function, blood sugar and, for some therapies, markers relevant to infection risk. If immune globulin is chosen, the first course is scheduled over several consecutive days. If plasma exchange is chosen, a series of sessions is arranged. If corticosteroids are chosen, monitoring for blood sugar and blood pressure begins.

Weeks two to six. This is the quiet stretch where many people feel they are waiting for nothing. Infusion-day side effects such as headache or tiredness may come and go. Some notice that the slide has stopped: no new stumbles, no new numb patches. A smaller number notice early gains in strength.

Weeks six to twelve. The first formal reassessment usually falls here. Measurements are repeated against baseline. If there is clear benefit, the conversation turns to maintenance: how often the treatment needs repeating to keep the gains, which is worked out individually. If there is no benefit, the team discusses whether to extend the trial or switch.

Throughout, physical therapy typically runs alongside. The NHS emphasizes exercise and rehabilitation in neuropathy care because strengthening the muscles that still work and protecting joints with reduced sensation pays off regardless of how the immune therapy performs. Expect referrals for physical and occupational therapy early, not as an afterthought once medication is settled.

Can CIDP nerve damage be reversed?

Partly, and the part that matters is which structure was damaged. This is the single most important idea for realistic expectations, so it deserves a full explanation.

Demyelination, the stripping of insulation, is largely reversible. Once the immune attack is controlled, Schwann cells lay down new myelin, and signals that were slowed or blocked begin to travel again. Weakness and numbness caused by demyelination alone can improve substantially, sometimes to near normal.

Axonal loss is different. When the inflammation has gone on long enough or hard enough, the wire inside the insulation is damaged and the nerve fiber dies back. NINDS explains that axons can regrow along their original path, but only slowly, at about an inch a month, and only if the surrounding nerve scaffold survives. For a nerve running from the lower spine to the toes, that is a journey measured in years, and regrowth is frequently incomplete. Muscles that have been disconnected for a long time also shrink and lose their ability to be reconnected.

This is why neurologists press for early diagnosis, and why the results of nerve conduction studies are worth asking about in plain terms. A study that shows mostly slowed conduction suggests a good deal of recoverable ground. One that shows very small or absent signals suggests axonal loss and a longer, more limited recovery for those specific nerves. Neither picture is a verdict on your whole body; different nerves are usually affected to different degrees.

A fair way to phrase the question at your appointment is: “Of my current weakness, how much do you think is myelin and how much is axon?” Most neurologists welcome the question because it lets them explain why they expect some things to return and others to plateau.

Why symptoms fluctuate during treatment, and what a wear-off pattern means

A common and unsettling experience in maintenance treatment goes like this: you feel stronger for a while after each course, then in the last stretch before the next one your feet drag again and the stairs get harder. People often wonder whether the disease is escaping the treatment. Usually it is not; it is the treatment’s effect wearing off before the next course.

Immune globulin and plasma exchange both act on antibodies that the body keeps producing. Their benefit is real but time-limited, so a sawtooth pattern of improvement and gentle decline between courses is expected. NINDS describes CIDP itself as a condition that can follow a relapsing course, with periods of worsening and recovery, and treatment schedules are designed around that rhythm.

What your neurologist wants to know is the shape of your particular sawtooth. If the wear-off begins well before the next planned course, the interval or the plan may need adjusting; that decision, and any change in how much or how often, rests entirely with the prescribing team. If the dips are shallow and brief, the current plan is probably right. Keeping a simple diary of a few functional markers, such as how many stairs before a pause or whether you can rise from a chair unaided, gives the team far better information than memory does.

Fluctuations have other causes too. Infections, poor sleep, heat and overexertion can all make neuropathy symptoms feel worse temporarily without any change in the underlying nerves. Fatigue often lags behind physical recovery. Distinguishing a bad week from a true relapse is genuinely hard, which is exactly why the reassessment measurements are repeated at every visit rather than left to impression.

One expectation to hold firmly: fluctuation is normal, and it is a reason to report and adjust, not a sign that the plan has failed.

When first-line CIDP treatment does not work well enough

Some people reach the end of a fair trial and the numbers have not moved. That is frustrating, but it is also common enough that neurologists have a well-worn pathway for it.

The first step is almost always to revisit the diagnosis. Several conditions can look like CIDP on initial testing, including neuropathies associated with abnormal blood proteins, hereditary neuropathies and rare variants of immune neuropathy that carry specific antibodies and respond differently. NINDS notes that CIDP is closely related to, and must be distinguished from, other inflammatory neuropathies. A repeat set of nerve studies, additional blood tests or, occasionally, a nerve biopsy may be ordered. Confirming that the target is right is more useful than switching therapies blindly.

The second step is to try a different first-line option. Because immune globulin, corticosteroids and plasma exchange work through different mechanisms, failure of one does not predict failure of another, and switching is standard practice. Sometimes two are combined for a period.

The third step, for people who respond poorly to all three or cannot tolerate them, involves other immune-modifying medicines, sometimes described as immunosuppressants, which reduce the activity of the immune cells producing the harmful response. MedlinePlus lists such medicines among the approaches used. The evidence base for them in CIDP is thinner than for the three standard options, meaning that benefit is less predictable and the trade-offs, including infection risk and monitoring requirements, are discussed carefully. Newer targeted therapies continue to be studied; where a neurologist mentions one, it is reasonable to ask what the evidence actually shows rather than what is hoped.

Throughout this process, rehabilitation, pain management and mobility aids continue to matter. Not responding to immune therapy is not the same as having no options for function.

Can CIDP go into remission, and does treatment ever stop?

Yes, remission happens, and the question of whether treatment can ever be withdrawn is one of the most reasonable to raise early, because the answer shapes how you plan the next few years.

Remission in CIDP means that the disease is no longer active: no progression, stable or improved strength, and no need for ongoing immune therapy to hold that position. NINDS describes the course of CIDP as variable, with some people experiencing a single episode that improves, others a relapsing pattern, and others a steadily progressive form. The relapsing and single-episode patterns are the ones in which treatment-free periods are most plausible.

How neurologists approach it is cautious by design. Once someone has been stable on maintenance therapy for an extended period, the team may propose lengthening the interval between courses or reducing the intensity of treatment while watching closely for any slide. If function holds, they may go further, eventually pausing treatment altogether with a plan to restart at the first sign of relapse. If function dips, they step back to the previous level. This is a supervised experiment, never a unilateral decision, and it is not something to attempt on your own by skipping or stretching scheduled courses.

The likelihood of achieving a lasting treatment-free remission cannot be stated as a reliable figure for an individual, and any percentage you encounter online should be treated as a population average from a specific study rather than a personal forecast. What can be said is that relapses after stopping are common enough that most teams keep people under regular review for a long time even when things are going well.

A fair expectation, then: remission is a real possibility worth aiming for, treatment may become lighter over time, and long-term follow-up continues regardless.

Rehabilitation, exercise and living with what remains

Immune therapy stops the fire. Rehabilitation rebuilds the house, and it does much of the work that people later credit to medication.

Physical therapy in CIDP focuses on three things. Strengthening the muscles that still have working nerve supply, so they compensate for weaker ones. Preserving joint range, because a muscle that cannot lift a foot lets the ankle stiffen into a drop position. And retraining balance, which depends heavily on foot sensation and needs deliberate practice when that sensation is dulled. The NHS advises that exercise and physical therapy help people with peripheral neuropathy maintain strength and mobility, and this applies as much when the cause is immune as when it is metabolic.

Occupational therapy addresses hands and daily living. Adapted utensils, jar openers, button hooks and changes to how a kitchen is arranged can restore independence long before strength returns, if it returns. Ankle braces that support a dropped foot reduce trips and let people walk farther and safer.

Skin and feet need attention when sensation is reduced. Mayo Clinic advises people with neuropathy to inspect their feet daily for cuts, blisters and pressure spots, wear well-fitting shoes and avoid extreme temperatures, because injuries that would normally hurt can go unnoticed and become infected.

Pain is treated on its own track. The NHS describes medicine classes commonly used for neuropathic pain, including certain antidepressants and anticonvulsants that act on nerve signaling rather than on mood or seizures in this context; whether any are appropriate for you is a decision for your prescribing clinician, and they do not treat the underlying CIDP.

Expect rehabilitation to be lifelong in a low-key way: a home program, periodic check-ins, adjustments as strength changes. It is the part of CIDP care where your own effort most directly changes the result.

What people often get wrong about CIDP treatment

Myths about CIDP cluster around speed, permanence and blame. Correcting them early saves a great deal of unnecessary despair.

Myth: if treatment worked, I would feel better after the first session. Reality: the first job of therapy is to stop progression. Visible gains lag behind, sometimes by weeks, and axonal recovery lags by months. A stable examination six weeks in is a success, not a stalemate.

Myth: the numbness will go away completely once the immune system is controlled. Reality: sensory fibers to the feet are long and often carry axonal damage by the time of diagnosis. NINDS notes that sensory loss can persist. Many people regain strength and balance while some numbness remains, and planning for that is more useful than waiting for it to vanish.

Myth: needing maintenance treatment means the first treatment failed. Reality: CIDP is a chronic condition. Ongoing therapy that holds function steady is the expected pattern for many, and the ability to lengthen intervals over time is a sign of good control, not of dependence.

Myth: a bad week means relapse. Reality: infection, heat, poor sleep and overexertion all worsen symptoms temporarily. Relapse is judged by measured decline on examination, which is why those repeated tests matter.

Myth: CIDP is caused by something I did or ate. Reality: NINDS describes CIDP as an autoimmune disorder with no established trigger in most cases. Lifestyle affects how well you cope with it, not whether you got it.

Myth: supplements or special diets can replace immune therapy. Reality: no supplement has been shown to treat the immune attack in CIDP. Correcting a confirmed vitamin deficiency, if your team finds one, is sensible; substituting an unproven product for evidence-based treatment risks the very axonal loss that limits recovery.

What to expect from CIDP treatment over the years: long-term prognosis

Ask about the long view and most neurologists will resist giving you a single trajectory, because CIDP does not have one. NINDS describes three broad patterns: a single episode with recovery, a relapsing and remitting course, and a chronically progressive course. Which pattern you follow becomes clearer over the first year or two of treatment, and the plan bends to fit it.

For the relapsing pattern, the long-term picture usually involves maintenance therapy with periodic attempts to lighten it, punctuated by occasional relapses that are treated by stepping back up. Function often stays good if relapses are caught early, which is the practical reason for keeping regular appointments even in quiet stretches.

For the progressive pattern, the goal shifts toward slowing decline and preserving independence. Here the combination of immune therapy, rehabilitation and adaptive equipment matters most, and honest conversations about what the coming years might look like help families plan.

Across all patterns, a few things shape the long-term outlook. Earlier diagnosis and treatment generally mean less axonal loss and more recoverable function, a point NINDS emphasizes. Good response to a first-line therapy is a favorable sign. Age and other health conditions influence both how well the nerves recover and which treatments are safe to continue for years.

Long-term treatment also brings its own maintenance work. People on corticosteroids need bone density and blood sugar checks. People on long-term immune globulin have kidney function and infusion reactions monitored. People on immunosuppressants are watched for infection. None of this is optional, and building it into your calendar is part of what to expect from CIDP treatment as a chronic condition rather than a course you finish.

The realistic hope, then, is not an ending but a well-managed steadiness: control of the disease, protection of what has recovered, and a team that knows your baseline well enough to act quickly when it shifts.

Questions to ask your care team before and during treatment

The most productive appointments are the ones where you arrive with specific questions and leave with specific answers. These are the ones that tend to matter most in CIDP.

• How confident are you in the diagnosis, and what other conditions have you ruled out?
• Looking at my nerve studies, how much of my weakness do you think is from myelin damage and how much from axonal loss?
• Which first-line option are you recommending for me, why that one, and what would be the fallback if it does not work?
• How long is the planned trial before we judge whether it is working, and what measurements will you use to decide?
• What side effects should I expect around treatment days, and which ones should make me call you?
• What does maintenance look like if the treatment works, and how will you decide whether it can be lightened over time?
• What monitoring tests will I need, and how often?
• Should I be referred now for physical and occupational therapy, and is a brace or other aid worth considering?
• What should I do about work, driving or travel while the plan is being established?
• If I get an infection or need surgery, does my treatment schedule change, and whom do I contact?
• How can I track my own function between visits in a way that is useful to you?

Bring someone with you if you can, and write the answers down. It is also reasonable to ask for a copy of your disability scores and nerve study results so that you can follow your own trend over time. A team that welcomes these questions is a team that will take your reports of change seriously later, which is the single most useful thing you can have in a long-term condition.

When to call your doctor during CIDP treatment

Most of CIDP care runs on scheduled appointments, but some changes should not wait for the next one. Knowing the difference between an ordinary fluctuation and a red flag is part of realistic expectations, and it is worth agreeing the list with your team so there is no hesitation when something happens.

Call your neurology team promptly, the same day if possible, if you notice a clear and rapid loss of strength over days rather than weeks, new difficulty gripping or lifting that was not there at your last visit, an increase in falls or near-falls, or new numbness spreading to areas that were previously unaffected. These can signal a relapse, and NINDS notes that prompt treatment of active disease helps limit lasting damage.

Seek urgent or emergency care without waiting if you develop any difficulty breathing, shortness of breath when lying flat, trouble swallowing or a weak or changed voice, new facial weakness, or an inability to stand or walk that has come on quickly. Weakness of the muscles that support breathing is uncommon in CIDP but can be serious.

Treatment-related symptoms also have their own red flags. During or after an immune globulin infusion, a severe headache with a stiff neck, chest pain, one-sided limb pain or swelling, sudden shortness of breath, a marked drop in urine output, or a spreading rash all warrant urgent contact. On corticosteroids, severe abdominal pain, black or bloody stools, very high blood sugar readings if you monitor them, or sudden mood changes should be reported. On any immune-suppressing therapy, a fever, persistent cough, painful urination or a wound that will not heal should be assessed quickly because infections can escalate faster than usual.

If you are unsure whether something counts, call. Teams that manage CIDP would far rather hear about a false alarm than learn about a real one at the next scheduled visit.

Frequently asked questions

How quickly does CIDP treatment work?

It depends on the therapy and on how much nerve damage exists. Plasma exchange can act within days but wears off over weeks; immune globulin often shows benefit within a few weeks of the first course; corticosteroids usually take weeks to a few months. Teams generally judge response after a defined trial period rather than after a single session, and stopping further decline counts as an early success.

Can CIDP nerve damage be reversed?

Partly. Damage to myelin, the insulating coating of nerves, is largely reversible once the immune attack is controlled, so strength can return well. Damage to the nerve fibers themselves, called axonal loss, recovers slowly and often incompletely, because axons regrow at roughly an inch a month according to NINDS. Nerve conduction studies help your neurologist estimate which type dominates in your case.

Can CIDP go into remission and treatment stop?

Yes, some people reach a stable phase in which treatment can be lightened and eventually paused under close supervision, with a plan to restart if symptoms return. Others need long-term maintenance therapy. Because relapses after stopping are common enough to matter, most teams continue regular follow-up for years even when things are going well. Any change in schedule should come from your treating team, not from skipping courses.

What is the long-term prognosis for CIDP?

NINDS describes three broad courses: a single episode with recovery, a relapsing and remitting pattern, and a steadily progressive form. Which one you follow usually becomes clearer over the first year or two of treatment. Earlier treatment, a good response to a first-line option and fewer other health conditions are generally favorable signs, but no reliable individual forecast can be made at diagnosis.

Why do my symptoms get worse before my next infusion?

Immune globulin and plasma exchange act on antibodies that the body keeps producing, so their effect is real but time-limited. A gentle decline in the days before the next scheduled course is a recognized wear-off pattern. Report its timing to your neurologist, ideally with a simple diary of function; the team may adjust the plan. Infections, heat, poor sleep and overexertion can also cause temporary dips.

Will the numbness in my feet go away with treatment?

It may improve but often does not disappear completely. Sensory fibers to the feet are among the longest in the body and frequently carry axonal damage by the time of diagnosis, which recovers slowly and partially. Many people regain strength and balance while some numbness persists, so foot care, well-fitting shoes and daily skin checks remain important even when treatment is working.

What happens if the first CIDP treatment does not work?

The team usually re-examines the diagnosis first, since several conditions mimic CIDP and respond differently. If the diagnosis holds, switching to a different first-line option is standard, because immune globulin, corticosteroids and plasma exchange work through different mechanisms. For people who respond poorly to all three, other immune-modifying medicines may be considered, with a frank discussion of their thinner evidence base and monitoring needs.

Does physical therapy help CIDP?

Yes, alongside immune therapy rather than instead of it. Physical therapy strengthens muscles that still have working nerve supply, keeps joints mobile and retrains balance, while occupational therapy addresses hand function and daily tasks. The NHS advises exercise and rehabilitation for peripheral neuropathy generally. Braces for a dropped foot can reduce trips and extend safe walking distance regardless of how quickly the nerves recover.

Are the side effects of long-term CIDP treatment serious?

They can be, which is why monitoring is built into every long-term plan. Immune globulin commonly causes headache and fatigue around infusions and rarely affects kidneys or clotting. Corticosteroids over time can affect blood sugar, bones, weight, mood and infection risk. Immune-suppressing medicines raise infection risk. Your team weighs these against the harm of untreated disease and schedules tests to catch problems early.

When should I call my doctor during CIDP treatment?

Call the same day for rapid strength loss over days, new numbness spreading to new areas, or a jump in falls. Seek emergency care for breathing or swallowing difficulty, a changed voice, new facial weakness or sudden inability to walk. Around infusions, severe headache with stiff neck, chest pain, one-sided limb swelling or breathlessness need urgent attention. On immune-suppressing therapy, fever or a persistent cough should be assessed promptly.

References

• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), National Institute of Neurological Disorders and Stroke (NIH)
• Peripheral Neuropathy, National Institute of Neurological Disorders and Stroke (NIH)
• Chronic inflammatory polyneuropathy, MedlinePlus Medical Encyclopedia
• Peripheral neuropathy: Treatment, NHS

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.